Here you will find the recommendations we have made about the use of individual medicines in Lancashire.


Brand: Latuda ®
Indication: Treatment of schizophrenia in adults aged 18 and over
Disease category: Central nervous system
Commissioning responsibility: CCG
PbR excluded: No


Lurasidone will be supplied by the specialist service for the duration of the treatment course.
Primary care initiation or continuation of treatment is not recommended unless exceptional circumstances such as specialist GP.
Lurasidone may only be prescribed in the following circumstances:
1. The patient has previously had a trial of and has not responded to aripiprazole
2. The patient does not fulfil the treatment resistance criteria as outlined in NICE Clinical Guideline 178 for the initiation of prescribing of clozapine
3. The patient has:
a. a metabolic disorder, diabetes or obesity or
b. pre-existing risk factors for metabolic disease, diabetes or obesity
All requests for lurasidone will be screened by the pharmacy department of the specialist service provider.
Based on current prescribing patterns, the number patients eligible for treatment with lurasidone is expected to be very low (fewer than around five patients per year).


LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

New Medicine Recommendation - Lurasidone (633.8 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG




Red (Restricted)